Last reviewed 2026-04-23 · How we verify

Lucanix™

Lucanix is a dendritic cell-based cancer vaccine that activates the immune system to recognize and attack tumor cells expressing PRAME antigen.

Lucanix is a dendritic cell-based cancer vaccine that activates the immune system to recognize and attack tumor cells expressing PRAME antigen. Used for Melanoma (adjuvant setting), Non-small cell lung cancer.

At a glance

Mechanism of action

Lucanix is an autologous dendritic cell vaccine engineered to present the PRAME (preferentially expressed antigen in melanoma) tumor-associated antigen to the patient's immune system. The vaccine is designed to stimulate CD8+ T-cell responses against PRAME-expressing cancer cells, thereby enhancing anti-tumor immunity. This approach aims to provide durable immunological memory and reduce recurrence risk in cancer patients.

Approved indications

• Melanoma (adjuvant setting)
• Non-small cell lung cancer

Common side effects

• Injection site reactions
• Fever
• Fatigue
• Chills

Key clinical trials

• Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (PHASE3)
• Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Lucanix™ CI brief — competitive landscape report
• Lucanix™ updates RSS · CI watch RSS
• NovaRx Corporation portfolio CI